

Cellular Bio gets NCI patent license for solid tumour immunotherapy

05 October 2018 | News

CBMG develops proprietary cell therapies for the treatment of cancer and degenerative diseases.



Cellular Biomedicine Group Inc. (CBMG), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, has entered into a Patent License Agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, within the Department of Health and Human Services.

Pursuant to the License Agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (TIL) technology to treat a variety of cancers.

CBMG develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China using products from the integrated GMP laboratory. The GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards.